Halozyme Therapeutics, Inc. provides earnings guidance for the year 2024. For the period, the company expects Total revenue of $915 million to $985 million, representing growth of 10% to 19% over 2023 total revenue primarily driven by increases in royalty revenue, collaboration revenue and growth in product sales from XYOSTED. Revenue from royalties of $500 million to $525 million, representing growth of 12% to 17% over 2023.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
43.84 USD | +4.37% | +9.32% | +17.78% |
05-07 | Halozyme Therapeutics Q1 Non-GAAP Earnings, Revenue Rise; 2024 Guidance Reaffirmed | MT |
05-07 | Transcript : Halozyme Therapeutics, Inc., Q1 2024 Earnings Call, May 07, 2024 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+17.78% | 5.34B | |
+3.04% | 108B | |
+10.36% | 105B | |
+1.57% | 23.46B | |
-12.82% | 21.72B | |
-7.05% | 18.64B | |
-37.64% | 17.45B | |
-7.27% | 17.19B | |
+6.12% | 13.99B | |
+37.01% | 12.53B |
- Stock Market
- Equities
- HALO Stock
- News Halozyme Therapeutics, Inc.
- Halozyme Therapeutics, Inc. Provides Earnings Guidance for the Year 2024